Sympathetic overactivity in hypertension: A risk factor for cardiovascular disease

被引:48
|
作者
Palatini P. [1 ]
机构
[1] Dipartimento di Medicina Clinica e Sperimentale, University of Padova, 35128 Padova, via Giustiniani
关键词
Left Ventricular Mass; High Heart Rate; Sympathetic Outflow; Moxonidine; Eprosartan;
D O I
10.1007/s11906-001-0065-z
中图分类号
学科分类号
摘要
Numerous prospective studies have shown that high heart rate is related to the development of hypertension, atherosclerosis, and incidence of cardiovascular events. Experimental studies in monkeys have shown that high heart rate has direct atherogenic effects on the arteries as a result of increased wall stress. However, clustering of several risk factors for coronary artery disease in persons with high heart rate suggests that sympathetic overactivity also accounts for part of the increased cardiovascular morbidity that is observed in persons with tachycardia. Indeed, experimental studies have shown that heightened sympathetic tone can cause obesity, hyperinsulinemia, and insulin resistance, which in the long term can promote the development of atherosclerosis. Through its interaction with plasma insulin, sympathetic overactivity can promote the development of left ventricular hypertrophy. Sympathetic activation can also increase hematocrit and precipitate a procoagulant state. Angiotensin II has an effect both on the central nervous system, enhancing sympathetic outflow, and on the peripheral sympathetic nerves. Among the angiotensin II receptor antagonists, eprosartan showed a particular ability to block presynaptic angiotensin II receptor 1(AT1) receptors at neuro-effector junctions in the sympathetic nervous system, as well as AT1 receptors in blood vessels. This dual action may represent an important advance in treatment of elevated blood pressure. Copyright © 2001 by Current Science Inc.
引用
收藏
页码:S3 / S9
页数:6
相关论文
共 50 条
  • [1] Sympathetic Overactivity in Hypertension and Cardiovascular Disease
    Manolis, A. J.
    Poulimenos, L. E.
    Kallistratos, M. S.
    Gavras, I
    Gavras, H.
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (01) : 4 - 15
  • [2] Sympathetic overactivity, hypertension and cardiovascular disease: state of the art
    Grassi, Guido
    Drager, Luciano F.
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 : 5 - 13
  • [3] Effect of sympathetic overactivity on cardiovascular prognosis in hypertension
    Julius, S
    EUROPEAN HEART JOURNAL, 1998, 19 : F14 - F18
  • [4] Sympathetic overactivity and coronary risk in hypertension.
    Amerena, J
    Julius, S
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1997, 11 : S78 - S81
  • [5] Sympathetic overactivity - The cinderella of cardiovascular risk factors in dialysis patients
    Vonend, Oliver
    Rump, L. Christian
    Ritz, Eberhard
    SEMINARS IN DIALYSIS, 2008, 21 (04) : 326 - 330
  • [6] Sympathetic Overactivity and Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease
    van Gestel, Arnoldus J. R.
    Kohler, Malcolm
    Clarenbach, Christian F.
    DISCOVERY MEDICINE, 2012, 14 (79) : 359 - 368
  • [7] Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease
    Ernsberger, P
    Koletsky, RJ
    Friedman, JE
    REVIEWS IN CONTEMPORARY PHARMACOTHERAPY, 1998, 9 (07): : 411 - 428
  • [8] The changing face of sympathetic overactivity in hypertension
    Julius, S
    Majahalme, S
    ANNALS OF MEDICINE, 2000, 32 (05) : 365 - 370
  • [9] Sympathetic overactivity in hypertension - A moving target
    Julius, S
    Nesbitt, S
    AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (11) : S113 - S120
  • [10] Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease
    Burnier, Michel
    Damianaki, Aikaterini
    CIRCULATION RESEARCH, 2023, 132 (08) : 1050 - 1063